Optina is a Montreal-based diagnostics company that focuses on retinal imaging and brain health. It has closed a funding round of up to US$2.1M.
The Alzheimer’s Drug Discovery Foundation (ADDF), made the investment through the ADDF’s Diagnostics Accelerator. This collaborative research initiative was supported by Leonard A. Lauder and Bill Gates, Jeff Bezos and MacKenzie Scott, as well as the Charles and Helen Schwab Foundation. This funding comes after the close of a Series A round by DigitalDx Ventures which included Desjardins Venture Fund, Boehringer Ingelheim Venture Fund and Zoic Capital, as well as other investors.
The new funding will be used to support Optina’s pivotal study in the FDA regulatory submission for the awAIr TM cerebral status test for Alzheimer’s disease detection. This will align Optina’s platform with new therapeutic approvals. This new funding will allow the company to increase its cohort size for its pivotal study. The clinical study will be conducted at five sites across the USA, Canada, and Europe.
David Lapointe is the CEO of Optina Diagnostics. The company has received FDA Breakthrough Device Designation status for its first indication in 2019. This non-invasive test improves diagnosis accuracy for patients undergoing treatment for Alzheimer’s disease (AD). It also received 501(k), clearance for the hyper-spectral Optina-4C TM cam in 2020.